A continuous human breast tumor cell line (BOT-2) was derived from an infiltrating duct carcinoma. The tumor cell line was grown as a monolayer in flasks, but the cells could be readily adapted to growth in roller cultures. These studies indicate that BOT-2 cells have a 16- to 18-hr doubling time and a modal chromosomal number of 63. The original BOT-2 cell culture has been in continuous cultivation for almost 2 years and has been passed 137 times. The BOT-2 cell line has been differentiated from HeLa cells by isoenzyme studies and chromosomal analysis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Recent Advancements in Drug Targeting for Ferroptosis as an Antitumor Therapy: Development of Novel therapeutics.
Curr Cancer Drug Targets
January 2025
Department of Chemistry, Siddhachalam Laboratory, Raipur, 493221, Chhattisgarh, India.
Objectives: The primary objective of this review is to provide updated mechanisms that regulate ferroptosis sensitivity in cancer cells and recent advancements in drug targeting for ferroptosis as an antitumor therapy.
Methods: To achieve these objectives, a comprehensive literature review was conducted, analyzing recent studies on ferroptosis, including its cellular, molecular, and gene-level characteristics. The review involved an evaluation of advancements in ferroptosis drug research across various medical domains, with particular attention to novel therapeutic approaches in nano-medicine, TCM, and Western medicine.
Revealing miRNAs' Janus-Faced Nature: Transforming Cold Tumours into Immunotherapy Hotspots and Overcoming Chemoresistance.
Microrna
January 2025
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, 20130, India.
MicroRNA (miRNA) modulation has emerged as a promising strategy in cancer immunotherapy, particularly in converting "cold" tumors with limited immune cell infiltration into "hot" tumors responsive to immunotherapy. miRNAs regulate immune cell recruitment and activation within the tumor microenvironment, influencing tumor behavior targeting specific miRNAs in cold tumors aims to enhance the immune response, potentially improving therapeutic efficacy. Despite ongoing research challenges, such as tumor complexity and treatment resistance, miRNA-based therapies offer personalized approaches with potential ethical considerations.
View Article and Find Full Text PDFTherapeutic potential of chalcone-1,2,3-triazole hybrids as anti-tumour agents: a systematic review and SAR studies.
Future Med Chem
January 2025
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.
The study of chalcone-1,2,3-triazole hybrids for anticancer activity is quite a recent area of focus, primarily because of the increasing demand for developing new drugs to treat cancer. The chalcones and 1,2,3-triazole rings in hybrid compounds has recently emerged as a promising strategy for developing novel anticancer agents. The 1,2,3-triazole ring, known for its stability and hydrogen bonding capabilities, enhances the target binding affinity of these hybrids.
View Article and Find Full Text PDFSMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series.
Sci Prog
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Despite advances in multimodal cancer therapy, such as combining radical surgery with high-intensity chemoradiotherapy, for SMARCB1/INI-1-deficient sinonasal carcinoma (SDSC), the prognosis of patients remains poor. Immunotherapy is gaining increasing popularity as a novel treatment strategy for patients with SMARCB1/INI-1-deficient tumors. Herein, we report on the management of three patients with SDSC who received PD-1/PD-L1 inhibitor therapy as a part of multimodal therapy based on surgery and chemoradiotherapy.
View Article and Find Full Text PDFClinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and Vulva.
Am J Surg Pathol
January 2025
Department of Pathology.
Despite being designated as "noncarcinogenic" human papillomavirus (HPV) types, mono-infection with HPV6 or HPV11 has been found in squamous cell carcinomas (SCCs) at specific sites, including the larynx, penis, anus, and rarely, the lower female genital tract. The association between clinicopathologic features, viral status, and the carcinogenic mechanisms related to these low-risk HPVs remains unclear. The current study characterizes a series of low-risk HPV6 and HPV11-associated SCCs of the uterine cervix (6 cases) and vulva (2 cases).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!